Evoke Pharma Announces Pricing of Initial Public Offering of 2,100,000 Shares of Common Stock

September 24, 2013

Evoke Pharma is developing drugs to treat GI disorders and diseases and is advancing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
More »

Achaogen Announces Agreement with FDA on a Special Protocol Assessment for a Phase 3 Clinical Trial of Plazomicin to Treat Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE)

September 23, 2013

This SPA indicates that the Phase 3 clinical trial, a superiority study to evaluate the efficacy and safety of plazomicin compared with colistin in patients with bloodstream infections and nosocomial pneumonia caused by CRE, will support a NDA.
More »

Celator® Pharmaceuticals Announces Start Of Clinical Study Of CPX-351 In Pediatric, Adolescent And Young Adult Patients With Relapsed Or Refractory Hematologic Malignancies

September 19, 2013

CPX-351 will be studied in two phases, a dose exploration phase and an expanded phase, in relapsed or refractory hematologic malignancies, which includes acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and aggressive lymphoma.
More »